财新传媒
财新英文 > 要闻 > 正文

In Depth: Where China Stands in the Nuclear Medicine Gold Rush

By Wen Simin
2025年11月21日 18:04
Billions are pouring into the domestic radiopharmaceutical industry as it races to catch up with global giants. But a shortage of talent and a ‘fast-follower’ mentality are proving to be major obstacles
Billions of dollars are pouring into China’s radiopharmaceutical industry as it races to catch up with global giants such as Novartis and its treatment Pluvicto.

Often tucked in out-of-the way corners of Chinese hospitals, nuclear medicine departments have for much of their history been mysterious places where few knew exactly what they do there.

What exactly they do there, though, is quickly becoming one of the more technologically promising fields of medicine and active areas of investment in the global pharmaceutical industry.

  [财新双语通产品,是为有双语需求读者专门订制的优惠产品, 按此可享超值优惠订阅。]

版面编辑:喻竹杨洋
财新网主编精选版电邮 样例
财新网新闻版电邮全新升级!财新网主编精心编写,每个工作日定时投递,篇篇重磅,可信可引。
订阅